Phoenix Rising tells QMUL: release the PACE trial data
Mark Berry, Acting CEO of Phoenix Rising, presents the Board of Directors’ open letter to Queen Mary University of London (QMUL) urging them to release the PACE trial data, and hopes that other non-UK organisations will join British charities in the same request...
Discuss the article on the Forums.

Status of Rituximab-ME/CFS Studies

Discussion in 'Rituximab: News and Research' started by Persimmon, Feb 15, 2012.

  1. lansbergen

    lansbergen Senior Member

    Messages:
    2,206
    Likes:
    1,879
    .
    My guess: If new Tcells are spared from this they might work properly but it will take time to get enouigh healthy Tcells.
     
  2. liquid sky

    liquid sky Senior Member

    Messages:
    371
    Likes:
    211
    "Ocrelizumab has previously been investigated as a treatment for rheumatoid arthritis but studies were discontinued because of a high incidence of opportunistic infections in participants. Opportunistic infections are infections that do not normally occur in a healthy person but may occur when the immune system is compromised."

    This new B cell depletion drug, Ocrelizumab, has not been safer than Rituxan. Rituxan has been approved for years in RA with a good safety profile. http://www.medpagetoday.com/MeetingCoverage/ACR/35895
     

See more popular forum discussions.

Share This Page